Back to Search
Start Over
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III)n-butoxyethylpyridylporphyrin-based redox modifier
- Source :
- Environmental and Molecular Mutagenesis. 57:372-381
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
-
Abstract
- Combinations of radiotherapy (RT) and chemotherapy have shown efficacy toward brain tumors. However, therapy-induced oxidative stress can damage normal brain tissue, resulting in both progressive neurocognitive loss and diminished quality of life. We have recently shown that MnTnBuOE-2-PyP(5+) (Mn(III)meso-tetrakis(N-n-butoxyethylpyridinium -2-yl)porphyrin) rescued RT-induced white matter damage in cranially-irradiated mice. Radiotherapy is not used in isolation for treatment of brain tumors; temozolomide is the standard-of-care for adult glioblastoma, whereas cisplatin is often used for treatment of pediatric brain tumors. Therefore, we evaluated the brain radiation mitigation ability of MnTnBuOE-2-PyP(5+) after either temozolomide or cisplatin was used singly or in combination with 10 Gy RT. MnTnBuOE-2-PyP(5+) accumulated in brains at low nanomolar levels. Histological and neurobehavioral testing showed a drastic decrease (1) of axon density in the corpus callosum and (2) rotorod and running wheel performance in the RT only treatment group, respectively. MnTnBuOE-2-PyP(5+) completely rescued this phenotype in irradiated animals. In the temozolomide groups, temozolomide/ RT treatment resulted in further decreased rotorod responses over RT alone. Again, MnTnBuOE-2-PyP(5+) treatment rescued the negative effects of both temozolomide ± RT on rotorod performance. While the cisplatin-treated groups did not give similar results as the temozolomide groups, inclusion of MnTnBuOE-2-PyP(5+) did not negatively affect rotorod performance. Additionally, MnTnBuOE-2-PyP(5+) sensitized glioblastomas to either RT ± temozolomide in flank tumor models. Mice treated with both MnTnBuOE-2-PyP(5+) and radio-/chemo-therapy herein demonstrated brain radiation mitigation. MnTnBuOE-2-PyP(5+) may well serve as a normal tissue radio-/chemo-mitigator adjuvant therapy to standard brain cancer treatment regimens. Environ. Mol. Mutagen. 57:372-381, 2016. © 2016 Wiley Periodicals, Inc.
- Subjects :
- 0301 basic medicine
Cisplatin
Chemotherapy
Temozolomide
Epidemiology
business.industry
Health, Toxicology and Mutagenesis
medicine.medical_treatment
Mutagen
Pharmacology
medicine.disease_cause
Radiation therapy
White matter
03 medical and health sciences
030104 developmental biology
medicine.anatomical_structure
Immunology
medicine
Adjuvant therapy
business
Genetics (clinical)
Oxidative stress
medicine.drug
Subjects
Details
- ISSN :
- 08936692
- Volume :
- 57
- Database :
- OpenAIRE
- Journal :
- Environmental and Molecular Mutagenesis
- Accession number :
- edsair.doi...........0528ebaab5c53e777b7015678fb9d69b